The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.

Adenine / analogs & derivatives Humans Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy Neoplasm Recurrence, Local / drug therapy Piperidines Pyrazoles / adverse effects Pyrimidines / adverse effects Retrospective Studies
Bruton tyrosine kinase Chronic lymphocytic leukemia Ibrutinib Relapsed/refractory p53 mutation

Journal

Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386

Informations de publication

Date de publication:
03 2022
Historique:
received: 08 08 2021
revised: 08 09 2021
accepted: 10 09 2021
pubmed: 12 10 2021
medline: 8 4 2022
entrez: 11 10 2021
Statut: ppublish

Résumé

The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.

Sections du résumé

INTRODUCTION/BACKGROUND
The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings.
PATIENTS/METHODS
A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers.
RESULTS
The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p
CONCLUSION
Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.

Identifiants

DOI: 10.1016/j.clml.2021.09.010 PMID: 34629286
pubmed: 34629286
pii: S2152-2650(21)02040-1
doi: 10.1016/j.clml.2021.09.010
pii:
doi:

Substances chimiques

Piperidines 0
Pyrazoles 0
Pyrimidines 0
ibrutinib 1X70OSD4VX
Adenine JAC85A2161

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-173

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Auteurs

Seval Akpinar (S)

Department of Internal Medicine, Division of Hematology, Tekirdağ Namık Kemal University Medical School, Tekirdağ, Turkey. Electronic address: seakpinar@nku.edu.tr.

Mehmet Hilmi Dogu (MH)

Liv Hospital Ulus, Department of Hematology, Istinye University, Istanbul, Turkey.

Serhat Celik (S)

Department of Hematology, Erciyes University, Kayseri, Turkey.

Omer Ekinci (O)

Department of Hematology, University of Health Sciences, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey.

Ipek Yonal Hindilerden (IY)

Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul, Turkey.

Mehmet Sinan Dal (MS)

Department of Hematology & Apheresis Unit, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey.

Eren Arslan Davulcu (EA)

Department of Hematology, University of Health Sciences, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Atakan Tekinalp (A)

Meram Faculty of Medicine, Department of Hematology, Necmettin Erbakan University, Konya, Turkey.

Fehmi Hindilerden (F)

Department of Hematology, University of Health Sciences, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Busra Gokce Ozcan (BG)

Department of Internal Medicine, Celal Bayar University, Manisa, Turkey.

Tuba Hacibekiroglu (T)

Department of Hematology, Sakarya University, Sakarya, Turkey.

Mehmet Ali Erkurt (MA)

Department of Hematology, Inonu University, Malatya, Turkey.

Metin Bagci (M)

Department of Hematology, Selcuk University, Konya, Turkey.

Sinem Namdaroglu (S)

Department of Hematology, University of Health Sciences, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.

Gulten Korkmaz (G)

Department of Hematology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Oktay Bilgir (O)

Department of Hematology, University of Health Sciences, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.

Gulsum Akgun Cagliyan (GA)

Department of Hematology, Pamukkale University, Denizli, Turkey.

Hacer Berna Afacan Ozturk (HBA)

Department of Hematology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Istemi Serin (I)

Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.

Tarık Onur Tiryaki (TO)

Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul, Turkey.

Duzgun Ozatli (D)

Department of Hematology, Ondokuz Mayis University, Samsun, Turkey.

Serdal Korkmaz (S)

Department of Hematology & Apheresis Unit, University of Health Sciences, Kayseri City Training and Research Hospital, Kayseri, Turkey.

Turgay Ulas (T)

School of Medicine, Department of Internal Medicine, Division of Hematology, Near East University, Nicosia, Cyprus.

Bulent Eser (B)

Department of Hematology, Medical Park Antalya Hospital, Antalya, Turkey.

Burhan Turgut (B)

Department of Internal Medicine, Division of Hematology, Tekirdağ Namık Kemal University Medical School, Tekirdağ, Turkey.

Fevzi Altuntas (F)

Department of Hematology & Apheresis Unit, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey; School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara Yildirim Beyazit University, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Purines › Adénine › The Real-World Experience With Single Agent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Real-World Experience With Single Agent...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie chronique lymphocytaire à cellules B › The Real-World Experience With Single Agent...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › The Real-World Experience With Single Agent...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › The Real-World Experience With Single Agent...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrazoles › The Real-World Experience With Single Agent...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › The Real-World Experience With Single Agent...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › The Real-World Experience With Single Agent...